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The objectives oftreatment for chronic heart failure, as for 
almost any disease, are threefold: prevention, relief of 
symptoms aad improvement of prognosis (Table 1). Major 
benefits have accrued to patients with heart ftiure from the 
availabiity of new drugs, the development of heart rans- 
plantation, improved iagnostic techniques and a better 
understanding of the pathophysiology of the condition. De 
spite such laudable achievements, liitations remain. Nota- 
bly, the mortality rate &om heart failure is unacceptably 
high, the most suitable treatment for individual patients is 
uncertain and knowledge ofthe underlying disease process i  
still deficient. This report is a commentary on selected 
clinically relevant problems. 
Several landmark trials (l-9) in the treatment of heart 
failure have been published in the last decade. Two impor- 
tant gains were made from these studies. The first was the 
demonstration that such studies could be carried out suc- 
cessfully. Previously, though it is easy to forget, the practi- 
cality of such trials was doubted because of the supposed 
need to monitor continually and adjust he treatment of 
patients with heart failure. The second gain was the acqui- 
sition of an overwhelming body of evidence showing that he 
addition ofangiotensin-converting enzyme inhibitors to con- 
venthmal therapy provided benefit n ‘;erms of symptomatic 
improvement, reduced hospital admissions, prevention 0f 
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the progression of heart faiiure, delay of death and, most 
surprisingly, prevention of coronary events. Though some 
negative trials remain unpublished, the bulk of evidence for 
the clinical benefit from angiotensin-converting enzyme in- 
hibitors contrasts with the sparse, or at least controversial, 
evidence for benefit from other drugs, notably vasodilators 
(10) and digozin (11,12). There are few well conducted trials 
of vasodilators including HO patients (10). The combination 
of hydralazine and nitrates has some advantage in reducing 
the incidence of death, but the side effects are substantial 
and greater benefit is obtained with an angiotensin- 
convertinq enzyme inhibitor (3). The recent vasodiitor 
tlosequiuan reduced the symptoms of patients with heart 
failure (13), but in a hii dose increases mortality. A 
ubiquitous role for beta-blockade or positively inotropic 
drugs is not defined and some trials (14,15) have been eutral 
or shown harm. 
Though such latge studies provide a clear answer to 
simple global questions, many issues facing the physician are 
unresolved. Patients do not want treatment solely because 
benefit was shown in a latyg study; rather, they want to 
know whether that particular form of treatment is appropri- 
ate for them and their individual condition. Subset analysis 
of the data in large studies is notoriously dangerous. Cardi- 
ologists are rightly cautious of such analyses at a time when 
several strongly held beliefs have been challenged by incon- 
venient facts. For that reason, most catdiologists will be 
seekingconlIrmatoryevidencefromsmallerstudiesincareMly 
selected homogeneous groups of patients and from an under- 
standing of the underiying pathologic mechanisms and princi- 
ples that provide alogical basis for individuahzing therapy. 
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Table 1. Obiectives ofTreatment i  Chronic Heart Failure 
I. Prevention 
Prevent myocardii damage 
Prevent occurrence of damage 
Frcvent progression f damage 
Prevent further damaging episodes 
Prevent recurrence of heart failure 
*vent symptoms 
Prevent fluid accumulation 
Prevent the need for hospitakation 
2. Relief of symptoms and signs 
Eliminate edema and fluid retention 
Increase exercise capacity 
Reduce fatigue and breathlessness 
3. Improved prognosis 
Reduce mortality 
Progression of Heart Failure 
Heart failure is a common condition with a poor progno- 
sis (16). The epidemiology has not been well described, 
partly because ofa lack of simple methods for establishing a 
precise diagnosis (17), and partly because of the emphasis 
that epidemiologists have hitherto placed on hypertension, 
hyperlipidemia and acute coronary events. Recent work has 
established that heart failure occurs in approximately 1% to 
2% of the population depending on age (IS), accoun?s for up 
to 5% of admissions toa general hospital t any one time and 
in such a hospital is as common aproblem as acute coronary 
events (19). The mortality rate is high, ranging from 50% in 
5 years for patients elected from a general population to 
50% in 1 year in those with advanced heart failure. athough 
death is delayed by treatment with angiotensin-converting 
enzyme inhibitors (3,4), the effect is modest and the residual 
mortality rate remains high, possibly 20% in 1 year. Surpris- 
ingly, little is known about he mechanisms for the progres- 
sion of heart failure. A popular concept is shown in Figure 1 
and some of the mechanisms are illustrated inFigure 2. What 
Figure 1. The progression of heart failure. An unknown proportion 
of patients with chronic heart failure experience progressively 
worsening heart failure, die suddenly, have a sudden additional l rge 
coronary event or have multiple small events. 
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is unclear is what proportion of patients within a population 
experience progression from ventricular dysfunction to 
death from progressive h art failure and how many patients 
follow a stepwise course because of further coronary events 
or exposure to the toxic or noxious agents that originally 
initiated heart failure. A proportion of patients die suddenly, 
but the definition of sudden death is arbitrary and this 
distinction is not informative in terms of establishing a 
mechanism. The real question is how many of these deaths 
are due to an opportunistic, potentially treatable arrhythmia 
and uaw many to further transient ischemic events, demon- 
strable worsening ofheart failure, the onset of atrial fibril- 
lation or the occurrence of cerebral or pulmonary embolism. 
Furthermore, ven if heart failure progresses, the mech- 
anism is not established (Fig. 2). A widely held view is that 
increasing myocardial wall stress leads to deterioration i  
the ability of the myocardium tocontract. If that were so, 
then most vasodiiators should be equally efficacious as 
angiotensin-converting e zyme inhibitors. Alternatively, 
progression may be related to interaction between the kid- 
ney and the heart or to remodeling within the heart muscle 
itself. 
Body Responses to Heart Failure 
Reduced function of the myocardium asa pump may arise 
from a systolic or diastolic abnormality. The consequence is 
lowered cardiac output. Unless peripheral resistance in- 
creases, blood pressure will decrease. The syndrome of 
heart failure has been described (20) as one in which the 
responses of the body are activated to maintain the blood 
pressure. These primitive reflexes were developed to main- 
tain the blood pressure for the purpose of sustaining sudden 
exercise and resisting the undesirable consequences of hem- 
orrhage. 
The major esponses of the body to heart failure occur in 
the heart, lungs, peripheral circulation and skeletal muscle 
(Tables 2 to 4) (21,22). A characteristic change is increased 
systemic resistance. The size of large conduit vessels is 
unaltered and only minimal changes have been shown in 
capillaries. It is possible that there are anatomic structural 
changes in vessels of a diameter between 200 and 4% fl 
because these vessels are too small to be seen by angiogra- 
phy and too large to be found in muscle biopsy specimens. 
Another reason for the increase in resistance could be 
atrophy of skeletal muscle with a major eduction i overall 
mass (22-24). Inevitably, peripheral resistance wilI increase 
if muscle mass is reduced. In the absence of any such 
anatomic explanation, the increased resistance must be 
attributed toa functional change in the vascular bed. Possi- 
ble uses include abnormalities of endothelial function, 
constriction of the smooth mu! ;A either in a latched state 
or as a consequence of altemons of sodium calcium ex- 
change, or to the effects of hormones uch as catechol- 
arnines, an@otensin, prostacyclin, bradyicinin a d en&the- 
lin. Activation of the sympathetic or renin-angiotensin 
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systems as a cause of increased resistance is unlikely be- 
cause short-term blockade of either system does not lead to 
a decrease in resistance atpeak exercise or an increase in 
exercise capacity. Bndothelial function has been shown to 
be abnormal in animal models of heart failure (25). The 
evidence in humans i more controversial. Endothelial func- 
tion cannot be assessed simply by measuring the response to 
agonists uch as acetylcholine or substance P. Nor is the 
hyperemic response a good measure ofendothelial function. 
Results may be dtfferent in the arm, where muscles are 
regularly used, than they are in the legs, where muscle mass 
is larger. Changes must be related to the state of the vessels 
under control conditions and the maximal abiity of the 
vessels to dilate. Both of these may be altered in heart 
failure, making the interpretation f incremental orpercent 
responses dilRcult. 
Anatomic hanges inskeletal muscle in heart failure have 
been well described (23,24,26-28). Some histologic hanges 
provide vidence of generalized myopathy (29,30), although 
that cannot be true of results in patients with coronary artery 
disease rather than dilated cardiomyopathy. Skeletal muscle 
undergoes atrophy and there is histologic evidence of dam- 
‘hbte 2. Body Responses to Heart Faihm 
1. Heart 
stlucture 
LOSS of CCUS, nbtmmal l&r 0kMation, change of size and shape, 
fibrosis, hypertrupkj 
FllIIctioo 
Systolic and/or diastolic dysfunction 
2. ciiulation 
s- 
? aWomic abnormality 
FUllCtiOll 
~~dne~docrineresponse (forexampksympatheticsystem 
and renin-aegiotensin system) 
Increased resistance, functional bnormality 
3. Skeletal muscle 
SkWtlKe 
Atrophy 
FUNtion 
Abnormalbiochemktry 
fncreased weakness and wp#ility 
aged muscle, possibly with a change in fiber type. As yet, 
there have been no longitudiil studies to show how fiber 
types in skeletal muscle change with the onset of heart 
failure. Current published reports involve comparisons be- 
tween fiber types in heart failure and small numbers of 
control patients. The control patients may not represent the 
population in general or the population from which the 
patients with heart failure were obtained. In a general 
population, there is a large spread in the proportion of 
muscle fiber types (23). The atrophied muscle could result 
from either epetitive ischemia on exercise or rtist atrophy. 
Neither condition is typical of the tindings in heart failure, 
although both could be contributory factors. Biochemical 
changes have been shown in muscle from patients with heart 
failure (26). Again, the interpretation f this data is compli- 
cated by the presence of atrophy, which may be heteroge- 
neous, an unknown internal work load on the muscle fiber, 
alteration i  the orientation and position of muscle fibers 
within the muscle and the effects of damaged cells or fiber 
Table 3. Underlying Causes of Chronic Heart Failure Due to 
the Myecardium* 
I. Loss of muscle 
2. Incoordiite contraction a d abnormal timing of contraction 
3. Extracelbdar 
Fibrosis, altered extracellular architecture, shape and size of ventricle 
SUppage of ceils, fiber tientation 
4. Cellular 
A. Change of cell suucture 
Myperkophy, ? hyperplasia, ? addition of sarcomeres 
B. Change of cell function-systolic and/or diastolic 
5. Calcium release and/or uptake 
Receptor downregulation 
Reduced CAMP 
Sarcoplasmic reticulum dysfunction 
Reduced number of ion channels orpumps 
6. Response of contractile ~IXGIIS to calcium 
Altered contractile proteins (isoforms) 
Altered phosphorylatiin of contractile proteins 
? energy-deticient sta e 
*Many of these factors combine to cause systolic or diastolic failure. 
Diastolic heart failure is common i the presence ofhypertmphy, fibrosis or 
ischemia. CAMP = cyclic adenosine monophosphate. 
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Table 4. Origin of Sym$omO * ’ ’ n11a “0Exerc:se in Chrocmc 
Heart Failure 
1. Lungs 
Increased stiffness due to raised venous pressure and lymph:tic 
distension 
Increased lefi atrial pressure 
Increased physiologic dead space 
Increased respiratory rate 
Weakness ofdiaphragm 
2. Circulation 
Reduced blood flow to skeletal muscle 
Increased production f metabolites 
Altered response tometabolites 
3. Skeletal muscle 
Rest atmphy 
Ischemic atrophy 
Specific abnormality 
Activation of ergoreceptors 
type change when biochemical bnormalities are sought 
using a technique that measures a mean change. The clinical 
consequence of muscle atrophy is that patients with heart 
failure have a reduction in peak strength and their muscles 
are more easily fatigued than those of normal subjects (27). 
Abnormality of the Myocardium in 
Heart Failure 
The possible mechanisms for a reduction i  myocardial 
function in patients with chronic heart failure due to disease 
of the myocardium are shown in Table 3. Loss of muscle is 
the most common cause, but this can be due either to an 
ischemic episode leading to myocardial necrosis or to ge- 
netic abnormalities, toxins or intlammation leading to dam- 
age of the myocardium in patients with dilated cardiomyop- 
athy. This latter type of damage is d#icult to assess at 
present because there is no simple method of measuring in
humans whether alarge heart is due to an increase infibrotic 
tissue, larger cells or larger cells with necrosis of a selected 
group of myocytes. A second and possibly unappreciated 
cause of pump failure is incoordinated contraction, which 
may be related not only to regional damage of the myocar- 
dium, but to alteration i the timing of electrical ctivation of
different parts of the myocardium. If pump failure cannot be 
explained by myocyte loss or incoordination f contraction, 
an abnormality of pump function must be attributed toeither 
extracellular o cellular changes. Much emphasis has re- 
cently been placed on extraceliular changes, which include 
not only fibrosis but also alterations in the shape of the heart, 
fiber orientation, cell slippage and cell damage (31-33). Cell 
damage includes vacuolation, loss of myofibrils and disorga- 
nization of the structural proteins within the myocyte. There 
is also the possibility that cells lengthen (34). 
Until recently, the most widely held belief has been that 
pump failure is due to an abnormality of the function of the 
myocytes in the myocardium. The evidence for this theory is 
“a* .-......A C....sn IIv, 6W~~. ,,~ti~ral studies (35-38) have reported little change 
in maximal tension development in multicellular muscle 
preparations obtained from patients in a transplant program. 
Similar information (39) has been obtained from isolated 
human ventricular cells. In animal models of hypertrophy, 
the reduction of ion channels eems to affect mechanisms 
concerned with relaxation of the myocardium rather than 
systems linked to contraction (40). The matter is controver- 
sial because others have claimed to show a reduction i peak 
tension development (41) and calcium transient (42). These 
issues are of major importance to a logical treatment of heart 
faihue because they determine whether t eatment should be 
aimed at altering thL function of the myocytes or preventing 
the change in the biology of the entire heart. An unresolved 
question iswhether the failing heart is in an energy-detlcient 
state (43); the evidence isnot clear (44,45). 
Causes and Symptoms in Heart Failure 
Traditionally, fatigue and shortness ofbreath ave been 
related to a low cardiac output and increased end-diastolic 
pressure. Although there may be some validity to this claim, 
recent studies have demonstrated that the origin of symp- 
toms in heart failure ;E much more complex (Table 4). In 
chronic heart failure, unlike acute heart failure, shortness of
breath is not related simply to end-diastolic pressurr either 
at rest or at peak exercise (46,47). Many subtle changes do 
take place in the lungs. The increased ventilation for a given 
carbon dioxide production and weakness of the diaphragm 
may be major factors. The altered peripheral circulation 
would result in earlier ischemia in the exercising muscle, 
with the aceutnuiation f metabolites. The interaction of 
those metabolites with receptors within the muscle may be 
modified by the changed neuroendocrine system. Finally, 
ergoreceptors within the muscle itself may contribute othe 
sensation of breathlessness, which is probably an accumu- 
lation of signals from the peripheral body and the lungs. 
Mechanism of Action of Angiotensh- 
Converting Enzyme Inhibitors 
The mechanism of action of the angiotensin-converting 
enzyme inhibitors remains unknown (Table 5, Fig. 2). The 
early idea that hese agents acted as vasodilators is probably 
untrue because other vasodilators are less effective in the 
treatment of heart failure. Angiotensin-converting e zyme 
inhibitors even in low doses (such as 1 mg of captopril]4!J]) 
interact with diuretic drugs to modify the function of the 
kidney. Recently, angiotensin-converting enzyme inhibitors 
have also been shown to prevent coronary events (6,8). The 
most popular concept at present is that hese agents act not 
only as vasodilators, but also have a tit effect on the heart 
to prevent remodeling orexpansion of the failing myocar- 
dium. This effect may be due not to the endocrine action of 
the rerun-angiotensin system, but to a tissue-renin system 
26A POOLE-WILSON 
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TPMC 5. Putative Mechanism of Action of Angiotensin- Table 6. Issues in the Use of Angiotensin-Converting Enzyme 
Converting Enzyme (ACE) Inhibitors (ACE) Mtibitors in Heart Disease 
1. vasodilation 
Reduction of myocardii stress 
2. Renal interaction with diuretic drvgs 
Increased net loss of sodium 
3. Remadelhql 
R6kacy in special patient groups 
1. Near normal ejection fraction 
2.>75yearsofage 
3. Female 
ventricular shape 
MY- hypertrophy 
Fibrosis 
4. Reduction of iscbemic episodes 
5. Mechanism unrelated to ACE inhibition 
4. Interaction with aspirin, vasodilators or diuretic drugs 
5. Patients treated with thrombolytic agents 
6. Benefit possibly greatest in those with substantial ventricular 
dysfunction, with ventricular enlargement or on diuretic drugs 
General questions 
1. Dose 
2. Low-acting or short-acting frequency of administration 
3. Benefit vs. side effects when used for prophylaxis 
4. Use of ACE inhibitors as sole treatment 
5. Possible increased incidence of gastrointestinal cancer 
6. Mechanism of benefit in heart failure, hypertension or coronary artery (49,50). Angiotensin II has marked proto-oncogenic ffects 
and may have a more important action on the growth and 
function of cells than on central hemodynamics in the 
circulation (49,50). Studies (51) in anephric humans show 
that the renin in the blood arises from the kidney. One 
genetic mode1 in the rat has shown that there can be 
activation of the renin-angioteasin system within tissues 
without achange inthe plasma concentrations; yet,hiih 
blood pressure is still present and responds to an angiotensin- 
converting enzyme inhibitor (52). At least in this model, there 
is no simple correlation between hypertension, blood can- 
centrations of hormones and the response to an angiotensin- 
converting enzyme inhibitor. Most of the components of the 
renin-angiotensin system exist within the heart. However, it 
is not clear how each component i eracts with each cell 
type or which cell type contains which components of the 
renin-angiotensin ystem. For example, angiotensin- 
converting enzyme appears toexist only in endothelial cells 
and not in the isolated myocyte (53). Although angiotensin II 
receptors exist on myocytes, the evidence that hese recep 
tars a&t the inotropic state of the human heart is contro- 
versial (SO). Some xperiments on animal species have been 
performed onthe intact heart where hemodynamic effects 
and actions on the coronary arteries are diiEcult to distin- 
guish from direct effects on the myocyte. Other experiments 
have been under&u on multicellular prepamtions where 
the influence of other cell types is uncertain. A recent report 
(54) on human ventricular tissue suggested hat angiotensin 
II did not have an inotropic effect. Furthermore, thema;ior 
cell stimulated by the renin-angiotensin system ay be the 
fibroblast and aldosterone rather than angiotensin II may be 
a key stimulant. Some recent work (55) suggests that angio- 
tensin II production in the human heart is generated by
chymase rather than by angiotensin-converting nzyme, 
Inhibition by angiotensin-converting nzyme ofthe break- 
down of kinins or actions of angiotensin-converting nzyme 
inhibitors unrelated to angiotensin-converting nzyme inhi- 
bition could be of importance. 
The prevention of coronary events by angiotensin- 
converting enzyme inhibitors poses the question as to 
ubtk much of the benefit from angiotensin-converting 
enxyme inhibition may be due to alteration fthe pmgre~s of 
disease 
7. Relation to benefits from a & se in bloud pressure 
8. Role in the prevention of coronary events relative to other drugs 
9. Possibly dierent mechanisms and dose for effects on mortality and 
symptoms 
heart failure consequent o  further damage. In the Studies of
Left Ventricular Dysfunction (SOLVD) (4,5,8), 25% of all 
deaths were preceded bya myocardial nfarction and death 
was much more wmmon in those sustaining aninfarction. 
Death from wronary artery disease accounts for 77% of 
deaths ina group of patients atrisk (56). The reduction of
deaths with angiotensin-converting nzyme inhibitors oc- 
curred only tier many months oftreatment (8). The effect is 
unlikely, therefore, to be due to an immediate effect on the 
thrombotic process at the time of infarction. Angiotensin- 
converting enzyme inhibitors confer little benefit in angina 
and can worsen angina because ofa steal effect. Possibly, 
the prevention f coronary events i due to lowering ofthe 
blood pressure and to stabilization f atheromatous plaques 
as a result of a growth effect on the arterial wall. 
Unresolved questluns with angiotensln-amv~g enayme 
inhibitors. Despite he impressive results from recent trials, 
many important issues exist with regard to the use of 
angiotensin-converting nzyme inhibitors inclinical practice 
(Table 6). Because ofthe large size of the studie, sucl ds 
the Survival nd Ventricular Enlargement (SAVE) trial (6) 
and SOLVD (4,5,8), subgroup analysis has been pos- 
sible. Although many questions have been resolved, many 
other tanMixing issues remain. These concern the use of 
angiotensin-wnverting enzyme inhibitors in those with a 
near-normal ejection fraction, the benefit inthe very old, the 
effect in women as well as men, a possible carcinogenic 
effect (4) and possible interactions with aspirin, vasodih&rs 
or diuretic drugs. In SOLVD, there appeared to be an 
interaction with aspirin, but this has not been confumed in 
SAVE study. The dose of diuretic drugs i  given in neither 
study, and in SAVE it is not clear whether the benefit 
occurred in those who were receiving diuretic drugs and 
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might herefore have au activated renin-angiotensin system. 
Only one-third of patients in the SAVE trial underwent 
thrombolysis, and the advantageous re ults in those who did 
receive thrombolysis may be determined by heart size. 
Thus, a group of patients may exist who have successful 
thrombolysis, a small heart and no indication for diuretic 
drugs in whom angiotensin-converting e zyme inhibitors 
would not confer any advantage. 
A mJor problem with angiotensin-converting e zyme 
inhibitors continues to be the dose. Not unreasonably, the 
large studies have been undertaken with a single-dose r gi- 
men. In SOLVD (57), the mean daily dose was 16 mg, 
contrasting markedly with higher doses previously studied 
and associated with hypotension and renal failure. Only 
one study (58) has reported a dose-response effect with 
angioteasin-converting enzyme inhibitors. Analysis of many 
other studies does not indicate a powerful dose-response 
effect. There are several possible reasons. The action of the 
angiotensin-converting e zyme inhibitor may be on the 
tissue-renin-angiotensin sy tem and not be related to blood 
concentrations of drug, hormones or angiotensin-converting 
enzyme activity. Even low doses of angiotensin-converting 
enzyme inhibitors may be sutlicient to achieve a maximal 
effect on the dose-response curve. The dose of angiotensiu- 
converting enzyme inhibitors required to have an effect on 
mortality, coronary events and exercise tolerance could be 
different. Certainly, captopril n a dose of 1 mg can have an 
effect on the kidney (48). Trials (ATLAS and NETWORK) 
are now addressing the issue of dose. 
Not only is the optimal dose unclear, but so is the need 
for a drug with a iong or shot-i tittrtii0fi of action (59). A short 
duration would be advantageous in limiting the hypotension 
that occurs on rare occasions after the first dose. In the 
long-term, once-daily drugs are more acceptable to patients. 
This question is unresolved because no relation has been 
established between effect and blood concentrations of drug 
or angiotensin-converting enzyme activity in blood. These 
problems of dose duration of action will bc resolved only by 
a direct comparison i clinical trials. 
The limitations of the use of angiotensin-converting en- 
zyme inhibitors for the treatment ofchronic heart faihue are 
only just beginning to be defined. Certainly, there is an 
advantage in patients who have a large heart and symptoms 
and are aheady beii treated with diuretic drugs. Even in the 
absence of obvious ymptoms or d..._ illrptjp &qy, flrp, h0p- 
pital stay is reduced and the progression of heart Ghue 
delayed (5). In such patients, angiotensin-wnvertin8 e zyme 
inhibitors could be initiated as sole early treatment, although 
it is unknown whether similar benefit would result from 
careful observation of the patient and initiation of therapy 
when there is clinical evidence of deterioration but before 
hospital admission. One study (68) has shown that he use of 
angiotensin-converting enzyme inhibitors alone to treat se- 
vere congestive heart failure is less beneficial than adminis- 
tration of diuretic drugs. The combination of the two drug 
types is needed. A second study (61) investigated whether 
angiotensin-converting enzyme inhibitors could be US& a~ 
sole treatment inpatients with treated heart failure who had 
a previous episode of undisputed heart failure associated 
with sodium and water etention. Four patients (2%) tern& 
nated the study because of puimonary edema or increasing 
shortness of breath. Thus, it seems that angiotensin- 
converting enzyme inhibitors are not sutBcient “ueatment 
once a patient has had an unequivocal episode of sodium and 
water etention. An important reason for these results may 
be the degree to which the renin-angiotensin ystem is 
activated in heart failure. Most early work demonstrating 
activation of the renin-angiotensin system was undertaken i  
patients already being treated with other drugs such as 
diuretic agents for heart failure. Three studies (17,62,63) 
have now shown that even in mild to moderate heart hihue, 
the renin-angiotensin system is not activated inthe absence 
of a diuretic drug. Because these patients have fluid overload 
and plasma renin activity and aldosterone are in the normal 
range, itmay be that he renin-angiotensin system is partially 
activated but has been suppressed by fluid retention. Nev- 
ertheless, the major increase in plasma renin activity and 
plasma ldosterone occurs with the introduction ofdiuretic 
drugs into treatment. The use of a diuretic drug appears to be 
an indication for adding an angiotensin-coiiverting enzyme 
inhibitor unless there is a contraindication. 
The remaining major question is whether angiotensin- 
converting enzyme inbrbitors are of long-term benefit in 
patients with ventricular damage who continue to have a 
small heart and are not being treated for overt heart failure; 
l L- .-.-.-..~PP l n *hi- nal.=etinn &II ~P~II~+P further Fzjor G&. U,b 4,,3"k, w L.."" mp""..".' ..-a ------ ------- 
Because angiotensin-converting e zyme inhibitors have 
been shown to reduce coronary events, the greater effect of 
an angiotensin-converting enzyme inhibitor may be on the 
recurrence ofcoronary events, rather than on any remodel- 
ing process. 
conclusions 
Substantial advances have been made in the treatment of
heart failure, but physicians should resist he temptation to
bask in the sunlight of success. Although angiotensin- 
converting enzyme inhibitors have been shown to have 
major benefit n patients with chronic heart faihue, the effect 
on the incidence of death is relatively small and a high 
mortality rate remains. In the future, tailoring of therapy to 
patients identified to have particular types of heart failure 
will prove crucial. This will require adetailed understanding 
of the patbophysiology of heart failure. The early detection, 
possibly by genetic techniques a  well as clinical expertise, 
of those at risk of mym&ial damage, albeit from wronary 
artery disease or cardiomyopathy, and of those in whom 
progression of that damage is probable should allow the 
more effective use of current and future therapeutic agents. 
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